ILD Conference, Prague 2014 - preliminary programme & call for
We are pleased to invite you to the conference and postgraduate
course on "Fibrosing interstitial lung
diseases of idiopathic and exogenous origin - Phenotype approach" which
will be held in the beautiful city of Prague (Czech Republique), June
19-21, 2014. View our flyer
Visit the official website at
The FSR Physicians’ Treatment Protocol
FSR (Foundation for Sarcoidosis Research) is committed to addressing
the gaps that exist in sarcoidosis research. This includes the lack
of information and knowledge around the current disease treatment
options. Yet another challenge of “rare disease” is the inherent
rarity of specialists and experts that can help guide treatment
options. While physicians who specialize in sarcoidosis can be
found, many times patients and doctors are challenged by a lack of
information. FSR’s Scientific Advisory Board developed a
Physicians’ Treatment Protocol
that can offer expert information
to physicians to help guide their diagnosis and treatment decisions.
Pulmonary Sarcoidosis: A Guide for the Practicing Clinician
Pulmonary Sarcoidosis: A Guide for the Practicing Clinician is a valuable resource for clinicians of varied disciplines concerning the care of the sarcoidosis patient. Chapters are written by distinguished authors who have extensive experience in caring for these patients.
This guide is fully comprehensive and evidence-based and will be an essential addition to the bookshelves of all whose practice involves the care and treatment of patients with sarcoidosis.
More details & order online
app for iPhone, iPad & Android
This app provides recommendations for the use of methotrexate in
sarcoidosis and everything else you need to know about methotrexate.
The app was developed on behalf of WASOG and is now available for iOS
and Android. Details & Download
How safe are the materials we insulate our houses with?
Experts ring alarm bells about the materials we use for insulation. Do
we have to worry too? You may find this dutch documentary - featuring
Prof. Marjolein Drent - with english subtitles in our online
The 3rd combined WASOG and BAL meeting will be held in Turkey on 8-11
October 2014. On behalf of the WASOG and Turkish Thoracic Society we are
pleased to invite you to the congress. The congress will be held in
Kusadasi which is a resort town near Izmir and ancient Ephesus.
For details visit the official congress website at
Follow WASOG on LinkedIn, Twitter and via our e-Newsletter
In addition to this website WASOG will keep you informed using
several media. Updates include WASOG news, conference updates and other
relevant information we would like to share with you. We therefore
invitite you to subscribe to our e-Newsletter
and/or follow @wasog on Twitter
You may also join our group on
to expand your professional network and participate in discussions.
Sarcoidosis and other ild around the world
To inform you about sarcoidosis and other ild in different countries we ask(ed)
colleagues to summarize the prevalence, the research and important websites, etc. This topic has been added to the WASOG site.
Multinational evidence-based WASOG recommendations for the use of
methotrexate in sarcoidosis: integrating systematic literature research
and expert opinion of sarcoidologists worldwide by Cremers JP et al.
Although glucocorticosteroids are considered the first-line treatment in
sarcoidosis, refractory cases require alternatives, such as methotrexate
(MTX). A systematic literature search was conducted and combined with
the opinions of sarcoidosis experts worldwide to formulate the
recommendations. Randomized controlled trial evidence supporting the use
of MTX in sarcoidosis was limited. Forty-five per cent (113 of 250) of
the sarcoidosis experts contacted completed the survey (Europe 55%,
North America 26% and Asia 12%). Ten recommendations were formulated
concerning the indications for use, starting dose, folic acid, work-up,
contraindications, monitoring, administration options in case of adverse
gastrointestinal effects, hepatotoxicity, long-term safety and use
during pregnancy and breast feeding.Ten multinational evidence-based
recommendations for the use of MTX in sarcoidosis were developed, which
are supported by the world's foremost sarcoidosis experts.
Read full paper
An official American Thoracic Society/European Respiratory Society
Statement: update of the international multidisciplinary classification
of the idiopathic interstitial pneumonias by Travis WD et al by
Travis WD et al. In 2002 the American Thoracic Society/European
Respiratory Society (ATS/ERS) classification of idiopathic interstitial
pneumonias (IIPs) defined seven specific entities, and provided
standardized terminology and diagnostic criteria. In addition, the
historical "gold standard" of histologic diagnosis was replaced by a
multidisciplinary approach. The objective of this statement is to update
the 2002 ATS/ERS classification of IIPs. The clinical course of
idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia is
recognized to be heterogeneous. Acute exacerbation of IIPs is now well
defined. A substantial percentage of patients with IIP are difficult to
classify, often due to mixed patterns of lung injury. A classification
based on observed disease behavior is proposed for patients who are
difficult to classify or for entities with heterogeneity in clinical
course. This update is a supplement to the previous 2002 IIP
classification document. It outlines advances in the past decade and
potential areas for future investigation.
Ten misconceptions about antioxidants by Bast & Haenen. Oxidative
damage is a common cellular event involved in numerous diseases and drug
toxicities. Antioxidants prevent or delay oxidative damage, and
therefore there has been extensive research into the discovery of
natural and newly designed antioxidants. Initial excitement regarding
the potential health benefits of antioxidants has diminished. Currently,
it is even claimed that antioxidants increase mortality. The antioxidant
pendulum appears to swing from healthy to toxic and from general panacea
to insignificant ingredient. Owing to the polarity of views towards
antioxidants, nutritional recommendation ranges from advice to increase
antioxidant status in plasma to the notion that it is a useless
measurement. Such views, lacking sufficient scientific support, lead to
misconceptions, which in our opinion hinder the rational use of food
supplements and impedes the design and development of new antioxidant
drugs. As a result, good opportunities might easily be missed.
The pathogenesis of pulmonary fibrosis: a moving target, by Wuyts
et al. Pulmonary fibrosis is the end stage of many diffuse parenchymal
lung diseases. It is characterised by excessive matrix formation leading
to destruction of the normal lung architecture and finally death.
Despite an exponential increase in our understanding of potentially
important mediators and mechanisms, the delineation of primary pathways
has proven to be elusive. Topics that are elaborated are candidate
ancillary pathways, including immune mechanisms, oxidative and
endoplasmic reticulum stress, activation of the coagulation cascade and
the potential role of stem cells. We believe that the integration of
current data into a "big picture" overview of fibrogenesis is essential
for the development of effective antifibrotic strategies.
Find all our selected literure on our